Products

ASX
LCT 0.033   Last updated 12.37 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Future development path

The 52 week results from the Phase IIb clinical trial of NTCELL in Parkinson’s disease will be analysed to see if a New Medicines Application for provisional consent to treat paying patients in New Zealand is warranted.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.